Cat. No：GM-C05619
Product：ADCC FcγRIIIa(158V) Jurkat Effector Cell Line
Cat. No：GM-C05619
Product：ADCC FcγRIIIa(158V) Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10%FBS+1%P.S+0.75μg/mL Puromycin+3.5μg/mL Blastincidin
Cell Freezing Medium：FBS+10% DMSO
Assay Buffer：RPMI 1640+1% low IgG FBS+1% P.S
ADCC, or antibody-dependent cell-mediated cytotoxicity, refers to the cytotoxic effect mediated by immune cells expressing Fc receptors, which directly kill target cells by recognizing the Fc portion of antibodies bound to them. Today, the ADCC mechanism is used to assess the efficacy of antibodies or target cells. The activation pathway of ADCC involves the binding of antibodies to target antigens on cell surfaces. When the Fc portion of antibodies binds to the FcγRIIIa receptor on effector cells (primarily natural killer cells), cross-linking occurs, leading to the activation of the ADCC mechanism. Cell killing of target cells is the endpoint of this activation pathway, which is used in classical ADCC bioactivity assays. These assays utilize peripheral blood mononuclear cells (PBMCs) or natural killer (NK) cell subsets from donors as effector cells. The response of these cells varies greatly, making them difficult to prepare and prone to high background readings.
ADCC Reporter cell lines focus on early events in the activation pathway of ADCC as readout indicators, specifically the activation of gene transcription mediated by the NFAT (nuclear factor of activated T cells) pathway in effector cells. Additionally, the ADCC reporter gene assay kit uses engineered Jurkat cells as effector cells, which stably express the FcγRIIIa receptor (high-affinity 158V) and firefly luciferase driven by NFAT response elements. The biological activity of antibodies in the ADCC mechanism is quantified by the luminescence produced through NFAT pathway activation, and the luminescence activity in effector cells is quantified by bioluminescent readings. The signal detection is high, with low background noise.
With years of research experience, Genomeditech offers ADCC-related cell lines and ADCC activity testing services using clever vector design and third-generation lentiviral reporter gene systems, and also provides customized ADCC cell line services.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC M_FcγRIV Jurkat Effector Cell Line |
| ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line | ADCP FcγRIIa Jurkat Effector Cell Line |
| ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line | |
Guo C, Dai X, Du Y, Xiong X, Gui X. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunol Immunother. 2024 Aug 9;73(10):210. doi: 10.1007/s00262-024-03794-3. PMID: 39123089; PMCID: PMC11315865.
Shen A, Liu W, Wang H, Zeng X, Wang M, Zhang D, Zhao Q, Fang Q, Wang F, Cheng L, Shen G, Li Y. A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells. Am J Cancer Res. 2023 Jul 15;13(7):3246-3256. PMID: 37559991; PMCID: PMC10408481.
Zhang M, Zhang Y, Wu H, Wang X, Zheng H, Feng J, Wang J, Luo L, Xiao H, Qiao C, Li X, Zheng Y, Huang W, Wang Y, Wang Y, Shi Y, Feng J, Chen G. Functional characterization of AF-04, an afucosylated anti-MARV GP antibody. Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166964. doi: 10.1016/j.bbadis.2023.166964. Epub 2023 Nov 22. Erratum in: Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167046. doi: 10.1016/j.bbadis.2024.167046. PMID: 37995774.
Cheng LS, Zhu M, Gao Y, Liu WT, Yin W, Zhou P, Zhu Z, Niu L, Zeng X, Zhang D, Fang Q, Wang F, Zhao Q, Zhang Y, Shen G. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. Cell Mol Biol Lett. 2023 May 31;28(1):47. doi: 10.1186/s11658-023-00461-w. PMID: 37259060; PMCID: PMC10230818.
Yue J, Shao S, Zhou J, Luo W, Xu Y, Zhang Q, Jiang J, Zhu MM. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function. Invest New Drugs. 2024 Feb;42(1):106-115. doi: 10.1007/s10637-024-01417-3. Epub 2024 Jan 10. PMID: 38198061.
Cat. No：GM-C05619
Product：ADCC FcγRIIIa(158V) Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10%FBS+1%P.S+0.75μg/mL Puromycin+3.5μg/mL Blastincidin
Cell Freezing Medium：FBS+10% DMSO
Assay Buffer：RPMI 1640+1% low IgG FBS+1% P.S
ADCC, or antibody-dependent cell-mediated cytotoxicity, refers to the cytotoxic effect mediated by immune cells expressing Fc receptors, which directly kill target cells by recognizing the Fc portion of antibodies bound to them. Today, the ADCC mechanism is used to assess the efficacy of antibodies or target cells. The activation pathway of ADCC involves the binding of antibodies to target antigens on cell surfaces. When the Fc portion of antibodies binds to the FcγRIIIa receptor on effector cells (primarily natural killer cells), cross-linking occurs, leading to the activation of the ADCC mechanism. Cell killing of target cells is the endpoint of this activation pathway, which is used in classical ADCC bioactivity assays. These assays utilize peripheral blood mononuclear cells (PBMCs) or natural killer (NK) cell subsets from donors as effector cells. The response of these cells varies greatly, making them difficult to prepare and prone to high background readings.
ADCC Reporter cell lines focus on early events in the activation pathway of ADCC as readout indicators, specifically the activation of gene transcription mediated by the NFAT (nuclear factor of activated T cells) pathway in effector cells. Additionally, the ADCC reporter gene assay kit uses engineered Jurkat cells as effector cells, which stably express the FcγRIIIa receptor (high-affinity 158V) and firefly luciferase driven by NFAT response elements. The biological activity of antibodies in the ADCC mechanism is quantified by the luminescence produced through NFAT pathway activation, and the luminescence activity in effector cells is quantified by bioluminescent readings. The signal detection is high, with low background noise.
With years of research experience, Genomeditech offers ADCC-related cell lines and ADCC activity testing services using clever vector design and third-generation lentiviral reporter gene systems, and also provides customized ADCC cell line services.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC M_FcγRIV Jurkat Effector Cell Line |
| ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line | ADCP FcγRIIa Jurkat Effector Cell Line |
| ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line | |
Guo C, Dai X, Du Y, Xiong X, Gui X. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunol Immunother. 2024 Aug 9;73(10):210. doi: 10.1007/s00262-024-03794-3. PMID: 39123089; PMCID: PMC11315865.
Shen A, Liu W, Wang H, Zeng X, Wang M, Zhang D, Zhao Q, Fang Q, Wang F, Cheng L, Shen G, Li Y. A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells. Am J Cancer Res. 2023 Jul 15;13(7):3246-3256. PMID: 37559991; PMCID: PMC10408481.
Zhang M, Zhang Y, Wu H, Wang X, Zheng H, Feng J, Wang J, Luo L, Xiao H, Qiao C, Li X, Zheng Y, Huang W, Wang Y, Wang Y, Shi Y, Feng J, Chen G. Functional characterization of AF-04, an afucosylated anti-MARV GP antibody. Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166964. doi: 10.1016/j.bbadis.2023.166964. Epub 2023 Nov 22. Erratum in: Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167046. doi: 10.1016/j.bbadis.2024.167046. PMID: 37995774.
Cheng LS, Zhu M, Gao Y, Liu WT, Yin W, Zhou P, Zhu Z, Niu L, Zeng X, Zhang D, Fang Q, Wang F, Zhao Q, Zhang Y, Shen G. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. Cell Mol Biol Lett. 2023 May 31;28(1):47. doi: 10.1186/s11658-023-00461-w. PMID: 37259060; PMCID: PMC10230818.
Yue J, Shao S, Zhou J, Luo W, Xu Y, Zhang Q, Jiang J, Zhu MM. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function. Invest New Drugs. 2024 Feb;42(1):106-115. doi: 10.1007/s10637-024-01417-3. Epub 2024 Jan 10. PMID: 38198061.
